التفاصيل البيبلوغرافية
| العنوان: |
Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. |
| المؤلفون: |
Hanren Dai1, Wenying Zhang2, Xiaolei Li3, Qingwang Han1, Yelei Guo1, Yajing Zhang2, Yao Wang1, Chunmeng Wang2, Fengxia Shi2, Yan Zhang2, Meixia Chen2, Kaichao Feng2, Quanshun Wang4, Hongli Zhu4, Xiaobing Fu2, Suxia Li4 lisuxia301@163.com, Weidong Han1,2,3 hanwdrsw69@yahoo.com |
| المصدر: |
OncoImmunology. Nov2015, Vol. 4 Issue 11, p1027469-1-1027469-12. 12p. |
| مصطلحات موضوعية: |
*T cell receptors, *CD19 antigen, *LEUKEMIA, *PROTEIN expression, *CYTOGENETICS |
| مستخلص: |
The engineering of T lymphocytes to express chimeric antigen receptors (CARs) aims to establish T cell-mediated tumor immunity rapidly. In this study, we conducted a pilot clinical trial of autologous or donor-derived T cells genetically modified to express a CAR targeting the B-cell antigen CD19 harboring 4-1BB and the CD3ζ moiety. All enrolled patients had relapsed or chemotherapy-refractory B-cell lineage acute lymphocytic leukemia (B-ALL). Of the nine patients, six had definite extramedullary involvement, and the rate of overall survival at 18 weeks was 56%. One of the two patients who received conditioning chemotherapy achieved a three-month durable complete response with partial regression of extramedullary lesions. Four of seven patients who did not receive conditioning chemotherapy achieved dramatic regression or a mixed response in the haematopoietic system and extramedullary tissues for two to nine months. Grade 2-3 graft-versus-host disease (GVHD) was observed in two patients who received substantial donor-derived anti-CD19 CART (chimeric antigen receptor-modified T) cells 3-4 weeks after cell infusions. These results show for the first time that donor-derived anti-CD19 CART cells can cause GVHD and regression of extramedullary B-ALL. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder